A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
It is a single-arm, open-label, multicenter, phase II study to evaluate the safety, efficacy,
pharmacokinetics (PK) and immunogenicity of AK104 as a single agent in subjects with
previously-treated locally advanced unresectable or metastatic MSI-H or dMMR solid tumors.